Compound heterozygosity for two GHR missense mutations in a patient affected by Laron Syndrome: A case report by Moia, Stefania et al.
CASE REPORT Open Access
Compound heterozygosity for two GHR
missense mutations in a patient affected by
Laron Syndrome: a case report
Stefania Moia1, Daniele Tessaris2, Silvia Einaudi2, Luisa de Sanctis2, Gianni Bona1, Simonetta Bellone1
and Flavia Prodam1,3*
Abstract
Background: Mutations localized in the Growth Hormone Receptor (GHR) gene are often associated with the
pathogenesis of Laron Syndrome, an autosomal recessive hereditary disorder characterized by severe growth
retardation. Biochemically, patients present normal to high circulating GH levels, in presence of very low or
undetectable IGF-I levels, which do not rise after rhGH treatment.
Case presentation: We describe the case of a 3.8 years old girl with symmetrical short stature (−3.76 SDS),
low IGF-1 and IGFBP-3, in presence of normal GH levels. Parents were not relatives and there was no family
history of short stature. During the second day of birth, she developed severe hypoglycaemia that required
glucose infusion. She presented frontal bossing and depressed nasal bridge. IGF-1 generation test showed no
response, suggesting a GH resistance evidence. In the hypothesis of Laron Syndrome, we decided to perform
a molecular analysis of Growth Hormone Receptor (GHR) gene. This analysis demonstrated that the patient
was compound heterozygote for two missense mutations.
Conclusions: GHR gene mutations are a well demonstrated cause of GH insensitivity. In heterozygous
patients, probably the normal stature may be achieved by a compensatory mechanism of GH secretion or
signalling. On the contrary, in homozygous or compound heterozygous patients these compensatory
mechanisms are inadequate, and short stature may be the consequence.
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Background
The Growth Hormone Receptor (GHR) is a type I trans-
membrane glycoprotein that belongs to the cytokine recep-
tor superfamily [1]. The human gene maps to chromosome
5p13.1–p12 and is composed by 10 exons, with exon 1 and
a large part of exon 10 that are untranslated regions and
most of exon 2 that encodes for the signal peptide [2, 3].
The signal peptide (residues 1–18) is later removed from
the mature protein that contains 638 amino acids [4]. In
particular, exon 2–7 of GHR gene encoded for the extracel-
lular domain of the receptor, involved in GH hormone
binding, exon 8 for the transmembrane domain and exon
9–10 encoded for the cytoplasmic domain that activates
the JAK-STAT signalling pathway [5, 6]. GHR is expressed
as a dimer on the cell surface, with a single GH molecule
that binds two GHRs extracellular domains sequentially
and induces a conformational change in the receptor, es-
sential for signal transduction [7].
Defects in the GHR protein, resulting from abnormal-
ities of the GHR gene, have been shown to result in the
clinical phenotypes of classical Growth Hormone Insensi-
tivity or Laron Syndrome [5, 8]. The first is clinically char-
acterized by severe postnatal growth failure and facial
dysmorphism, and biochemically by normal-to-elevated
circulating GH concentrations but deficiencies in circulat-
ing Insulin-like Growth Factor 1 (IGF-1) and Insulin-like
Growth Factor Binding Protein 3 (IGFBP-3) [9]. Laron
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Syndrome is an autosomal recessive hereditary disorder
characterized by severe growth retardation (height − 3 to
−10 standard deviation score [SDS]), small cranium with
underdeveloped facial bones, acromicria and organomi-
cria, obesity and hypogenitalism. In addition, circulating
GH levels are high in presence of low-to-undetectable
IGF-I levels, which do not rise after short-term or long-
term rhGH administration. The only treatment for Laron
Syndrome is daily rhIGF-I administration [10].
In this report, we described a child referred to our
Pediatric Endocrinology Department for a severe growth
failure, in presence of low IGF-1 and IGFBP-3, but normal
GH levels. After exclusion of a growth hormone deficiency
condition, we performed direct sequencing of GHR gene
sequence. This analysis demonstrated that the patient was
compound heterozygote for two missense mutations. In
particular, one of these mutations involved the first trans-
lation initiation codon of the protein. Consequently, the
correct expression of the receptor will be most likely
inhibited, probably causing the observed Laron phenotype.
Case presentation
We report a 3.8 years old girl who was referred to our
Pediatric Endocrinology Department for short stature.
At first evaluation she was 1.6 years old. She presented a
symmetrical short stature: height was 72.5 cm (−2.58
SDS), sitting height was 46.1 cm (−2.3 SDS), sitting
height/height ratio was 0.63 (0 SDS), weight was 8.2 kg
(−3.15 SDS) and head circumference was 46.8 cm (+0.31
SDS). She was prepuberal. Facial features included
frontal bossing and depressed nasal bridge. No other
congenital abnormalities were evident (Fig. 1). Subscapu-
lar skinfold was 18.4 mm, tricipital skinfold 12.5 mm.
She was born from a pregnancy of 36 + 5 weeks char-
acterized by gestational mellitus diabetes. Neonatal
weight was 2900 g (AGA), length was 47.7 cm (AGA),
head circumference was 33 cm (AGA) and Apgar score
was 9/10. During the second day of birth, she developed
severe hypoglycaemia that required glucose infusion.
Her father and mother are not related, with proportional
and normal height: mother height is 162 cm whereas
father height is 180 cm (target height 164.5 cm). There
are no cases of short stature in family members (only
child). Parents’ origin was from North of Italy and Sicily.
Biochemically, blood count, creatinine, liver function,
electrolytes, urine evaluation and serological screening
for celiac disease were normal. Her serum basal GH
levels were 11.57 ng/ml with glucose levels of 59 mg/dl,
IGF-1 19.1 ng/ml (−2.7 SDS) and IGFBP-3 0.7 mcg/ml
(2.0–4.5), respectively.
We failed to detect a positive response to the standard
IGF-1 generation test by administering 0.033 mg/kg/day
of rhGH for 4 consecutive days [IGF-1 d0: 13.6 ng/ml
(−2.6 SDS); IGF-1 d4: 8.4 ng/ml (−2.8 SDS)], indicating
a GH resistance.
Auxological follow-up for height is shown in Fig. 2.
At the age of 3.8 years old the height was 85.9 cm
(−3.76 SDS), weight 11.9 kg (−2.42 SDS), head circum-
ference 50 cm (0.52 SDS), and growth velocity deflected
at 5.29 cm/year (−1.80 SDS). Basal IGF-1 levels were
32 ng/ml (−2.28 SDS) and IGFBP-3 0.8 mcg/ml (2.0–
4.5). After a high dose of rhGH (2.8 mg/mq/die: 1.6 mg/
die for 7 days), stimulated IGF-1 levels were 62.0 ng/ml
(−1.78 SDS) and IGF1BP-3 0.9 mcg/ml (2.0–4.5). We de-
cided to start rhIGF-1 (0.5 mg twice daily s.c.: 0.04 mg/
kg/twice daily).
Fig. 1 Physical presentation at 3.8 years old
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In the hypothesis of a case of Laron Syndrome, we per-
formed the direct sequencing of the complete coding se-
quence of GHR gene that revealed the presence of two
heterozygous variation. The first is a missense mutation
caused by the transition adenine to guanine (c.1A > G) in
the first codon of exon 2. Given that, this substitution in-
volved the translation initiation codon (Methionine) of
the protein, the correct expression of the receptor will be
necessary inhibited. The second variation is the substitu-
tion c.307G > A, that resulted in the replacement of the
amino acid Aspartic Acid at position 103 to a residue of
Asparagine (p.D103N), in exon 5 of the GHR sequence.
This substitution involved the highly conserved Aspartic
Acid 103 and, as predicted by the PolyPhen-2 Program
(http://genetics.bwh.harvard.edu/pph2), it could be re-
sponsible for a damaging effect on GHR functionality.
Due to the identification of these variations in her daugh-
ter, the parents underwent a molecular analysis for GHR
gene mutation. The direct sequencing demonstrated that
the father was heterozygous for the first codon mutation,
whereas the mother was instead heterozygous for the
p.D103N variation.
Discussion and conclusions
Heterozygous mutations in the GHR sequence have
been frequently identified in children with idiopathic
short stature, and these mutations should be taken
into account when the other causes have been ruled
out [11–13]. Laron Syndrome is a genetic disorder
characterized by the inability to respond to endogen-
ous or exogenous GH. This disorder is characterized
by severe growth failure after birth, craniofacial dis-
proportion, elevated serum GH and low/undetectable
IGF-I levels that fail to respond to rhGH administra-
tion [3, 14].
In our patient, high doses of rhGH during IGF-1
generation tests demonstrated a partial response to
IGF-1 production, that probably reflects the mild
phenotype in her first years of life [15, 16]. After the
third year, due to the failure of compensatory mecha-
nisms, her growth velocity deflected and short stature
should require IGF-1 substitutive therapy to exceed
GH partial insensitivity [10].
Molecular analysis of the GHR gene demonstrated
the presence of the novel variation p.D103N, which
involved the highly conserved residue of Aspartic
Acid at position 103 of the extracellular domain. It is
well demonstrated that most of the mutations identi-
fied in children with short stature were localized in
the extracellular domain of the receptor, and are re-
sponsible of an impaired GH binding [12]. Consider-
ing that, the hormone binding and the subsequent
receptor dimerization, are essential steps to activate
the GHR signalling transduction, we can hypothesized
that our p.D103N variation is responsible of an im-
paired GH binding that causes an altered receptor
functionality.
The other mutation identified in our patient involved the
first ATG codon of the GHR sequence that encodes for the
Methionine necessary for the translation of all the mature
proteins. Because the first ATG is essential for the initiation
of the translation, this mutation certainly inhibits the cor-
rect expression of the receptor. A similar mutation was pre-
viously described by Quinteiro and co-workers, [17] in a
patient with Laron Syndrome. They observed that the suc-
cessive ATG codon is located in the sixth exon and encodes
for the methionine at position 188. Even if this mutation
could be able to start the receptor translation, the resulting
protein will be truncated by the first 187 amino acids and
will probably be not functional.
Fig. 2 Auxological follow-up – Females height for age WHO 2006
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It has been difficult to establish if the presence of
a heterozygous mutation in the GH receptor can re-
sult in clinically significant GH insensitivity, except
in the presence of a well-demonstrated dominant-
negative effect. It can be assumed that, in patients
who are heterozygous for a GHR mutation, the stat-
ure within the normal range may be achieved by a
compensatory mechanism of GH secretion or signal-
ling. On the contrary, homozygous or compound
heterozygous patients would manifest a clinical GH
insensitivity given that compensatory mechanisms
are inadequate, and short stature may be the conse-
quence [5].
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